Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Schrödinger, a little-known software company that helps some of the largest pharmaceutical brands with drug discovery, made its public debut. The company closed its initial public offering on Monday, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing it in line with the updated implied price target in the model. This mirrors recent Street research, ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development candidates into Novartis’s portfolio for further development. The ...

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial ...

Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc. (NASDAQ:SDGR) delivered solid fourth-quarter and full-year 2025 results characterized ...